Statements (74)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Regen-Cov
|
| gptkbp:accessories |
logistical issues during distribution
|
| gptkbp:activities |
neutralizes the virus
|
| gptkbp:advises |
administered as soon as possible after diagnosis
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:FDA
November 2020 |
| gptkbp:availability |
available in multiple countries
limited supply during peak demand |
| gptkbp:business_model |
adhered to in trials
|
| gptkbp:can_be_used_with |
gptkb:imdevimab
|
| gptkbp:class |
antiviral agent
|
| gptkbp:clinical_trial |
gptkb:United_States
gptkb:Regeneron_Pharmaceuticals Phase 3 randomized controlled trials post-exposure prophylaxis positive efficacy results multiple phases conducted Phase 3 results published open for eligible participants |
| gptkbp:collaborations |
healthcare providers
with academic institutions |
| gptkbp:developed_by |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:distribution |
managed by federal agencies
allocated by government agencies |
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:duration |
single administration
|
| gptkbp:education |
informed about potential side effects
|
| gptkbp:feedback |
generally positive
|
| gptkbp:frequency |
single dose
|
| gptkbp:healthcare |
facilitated through healthcare systems
|
| https://www.w3.org/2000/01/rdf-schema#label |
casirivimab
|
| gptkbp:impact |
significant in COVID-19 management
|
| gptkbp:indication |
mild to moderate COVID-19
|
| gptkbp:interacts_with |
other monoclonal antibodies
|
| gptkbp:invention |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:is_effective_against |
reduces hospitalization rates
|
| gptkbp:is_monitored_by |
monitor for allergic reactions
recommended after administration |
| gptkbp:is_used_for |
treatment of COVID-19
|
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:marketed_as |
gptkb:REGEN-COV
|
| gptkbp:part_of |
gptkb:REGEN-COV
|
| gptkbp:pharmacokinetics |
binds to the spike protein
half-life of approximately 20 days |
| gptkbp:population |
high-risk patients
|
| gptkbp:price |
varies by provider
|
| gptkbp:provides_information_on |
outpatient
recommended for certain patients updated regularly based on new data |
| gptkbp:publishes |
published in medical journals
|
| gptkbp:receives_funding_from |
funded by government grants
|
| gptkbp:regulatory_compliance |
Emergency Use Authorization
based on clinical trial results |
| gptkbp:research |
reduction in viral load
|
| gptkbp:research_focus |
COVID-19 variants
COVID-19 treatment options |
| gptkbp:safety_features |
generally well tolerated
collected from clinical trials ongoing post-marketing surveillance |
| gptkbp:scholarships |
available for eligible patients
|
| gptkbp:side_effect |
infusion-related reactions
mandatory for healthcare providers |
| gptkbp:student_enrollment |
must meet specific criteria
|
| gptkbp:supply_chain |
gptkb:monoclonal_antibody
due to high demand |
| gptkbp:targets |
SARS-Co V-2 virus
|
| gptkbp:treatment |
improved recovery rates
established for administration. shown in clinical studies |
| gptkbp:type_of_insurance |
covered by many insurance plans
|